Oscar Health (NYSE:OSCR) Price Target Raised to $33.00

Oscar Health (NYSE:OSCR) had its price target increased by Robert W. Baird from $27.00 to $33.00 in a report issued on Thursday, MarketBeat reports. The firm currently has a neutral rating on the stock.

Several other research firms also recently issued reports on OSCR. Zacks Research upgraded Oscar Health from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 6th. UBS Group raised their price objective on Oscar Health from $20.00 to $26.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Bank of America boosted their target price on Oscar Health from $28.00 to $30.00 and gave the stock an “underperform” rating in a report on Thursday. Piper Sandler reaffirmed an “overweight” rating and set a $36.00 target price on shares of Oscar Health in a research report on Tuesday, July 28th. Finally, Wall Street Zen upgraded Oscar Health from a “buy” rating to a “strong-buy” rating in a report on Sunday, June 14th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $33.90.

Oscar Health Stock Up 0.5%

Oscar Health stock opened at $32.14 on Thursday. The company has a market capitalization of $9.92 billion, a P/E ratio of 22.96, a P/E/G ratio of 0.46 and a beta of 2.37. The firm’s fifty day simple moving average is $30.75 and its 200-day simple moving average is $24.02. The company has a current ratio of 1.09, a quick ratio of 1.09 and a debt-to-equity ratio of 0.21. Oscar Health has a 1-year low of $10.69 and a 1-year high of $34.48.

Oscar Health (NYSE:OSCR) last issued its quarterly earnings data on Thursday, August 6th. The company reported $1.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.40 by $0.70. The firm had revenue of $4.88 billion during the quarter, compared to analysts’ expectations of $4.73 billion. Oscar Health had a net margin of 3.60% and a return on equity of 38.45%. Oscar Health’s revenue for the quarter was up 70.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.89) earnings per share. Sell-side analysts forecast that Oscar Health will post 1.74 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Richard Blackley sold 28,869 shares of the business’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $31.45, for a total transaction of $907,930.05. Following the completion of the transaction, the chief financial officer owned 1,046,108 shares of the company’s stock, valued at approximately $32,900,096.60. The trade was a 2.69% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Adam Mcananey sold 9,092 shares of the stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $31.45, for a total value of $285,943.40. Following the sale, the insider owned 209,004 shares of the company’s stock, valued at approximately $6,573,175.80. The trade was a 4.17% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 4,322,257 shares of company stock valued at $126,818,346 in the last quarter. Insiders own 22.64% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of OSCR. CoreCap Advisors LLC grew its stake in shares of Oscar Health by 526.3% in the second quarter. CoreCap Advisors LLC now owns 1,190 shares of the company’s stock worth $34,000 after acquiring an additional 1,000 shares during the last quarter. GAMMA Investing LLC increased its position in Oscar Health by 32.9% during the second quarter. GAMMA Investing LLC now owns 1,441 shares of the company’s stock worth $41,000 after acquiring an additional 357 shares during the period. FNY Investment Advisers LLC bought a new position in Oscar Health during the second quarter worth $57,000. Allworth Financial LP raised its stake in Oscar Health by 124.9% during the 2nd quarter. Allworth Financial LP now owns 2,031 shares of the company’s stock valued at $58,000 after purchasing an additional 1,128 shares during the last quarter. Finally, IFP Advisors Inc raised its stake in Oscar Health by 69.5% during the 2nd quarter. IFP Advisors Inc now owns 2,139 shares of the company’s stock valued at $61,000 after purchasing an additional 877 shares during the last quarter. 75.70% of the stock is currently owned by institutional investors and hedge funds.

Oscar Health News Summary

Here are the key news stories impacting Oscar Health this week:

• Positive Sentiment: Momentum and valuation support investor interest: Zacks identified Oscar Health as a potential “bargain” stock, citing its fast-paced share-price momentum alongside what it considers a reasonable valuation. Oscar was also included in Zacks’ Rank #1 (Strong Buy) growth-stock list. Despite Fast-paced Momentum, Oscar Health Is Still a Bargain Stock
• Positive Sentiment: ACA expansion provides a long-term growth catalyst: Oscar plans a major Obamacare expansion over the next three years. The strategy could increase membership and revenue, building on the company’s recent strong growth and improved profitability. Oscar Health Plans Major Obamacare Expansion Over Next Three Years
• Positive Sentiment: UBS sees meaningful longer-term potential: UBS said its 2029 outlook for Oscar is supported by solid revenue growth, reinforcing the bullish long-range investment case. Oscar Health’s 2029 Target Predicated on Solid Revenue Growth, UBS Says
• Neutral Sentiment: Analyst views remain mixed: Stephens reaffirmed an Equal Weight rating with a $34 target, while Baird raised its target to $33 but maintained a Neutral rating. These targets imply limited near-term upside and suggest analysts see balanced risk and reward. Analysts’ Opinions Are Mixed on Oscar Health
• Negative Sentiment: Key caveat: Oscar’s ACA-focused growth strategy remains exposed to changing government policy, subsidy conditions and the challenge of maintaining profitable growth as enrollment expands. Oscar Health’s Big ACA Gamble Is Paying Off—Here’s the Caveat

About Oscar Health

Oscar Health, Inc is a technology-focused health insurance company that offers health plans and related services to individuals, families and small businesses in the United States. The company’s primary business is providing Individual and Family plans through the Affordable Care Act marketplaces, along with health insurance options for small-group employers in select markets.

Oscar combines insurance coverage with digital tools designed to help members manage their care. Its offerings include online and mobile enrollment, virtual care, provider search and navigation services, claims and benefits information, and access to care teams.